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International cooperation to improve access to and sustain 
eff ectiveness of antimicrobials
Christine Årdal, Kevin Outterson, Steven J Hoff man, Abdul Ghafur, Mike Sharland, Nisha Ranganathan, Richard Smith, Anna Zorzet, 
Jennifer Cohn, Didier Pittet, Nils Daulaire, Chantal Morel, Zain Rizvi, Manica Balasegaram, Osman A Dar, David L Heymann, Alison H Holmes, 
Luke S P Moore, Ramanan Laxminarayan, Marc Mendelson, John-Arne Røttingen
Securing access to eff ective antimicrobials is one of the greatest challenges today. Until now, eff orts to address this 
issue have been isolated and uncoordinated, with little focus on sustainable and international solutions. Global 
collective action is necessary to improve access to life-saving antimicrobials, conserving them, and ensuring continued 
innovation. Access, conservation, and innovation are benefi cial when achieved independently, but much more 
eff ective and sustainable if implemented in concert within and across countries. WHO alone will not be able to drive 
these actions. It will require a multisector response (including the health, agriculture, and veterinary sectors), global 
coordination, and fi nancing mechanisms with suffi  cient mandates, authority, resources, and power. Fortunately, 
securing access to eff ective antimicrobials has fi nally gained a place on the global political agenda, and we call on 
policy makers to develop, endorse, and fi nance new global institutional arrangements that can ensure robust 
implementation and bold collective action.
Introduction
This Lancet Series has argued that both inadequate access 
to antimicrobials and antimicrobial resistance are 
daunting threats to both human and animal health—ie, a 
One Health approach is necessary to address these issues.1 
The most cost-eff ective and time-effi  cient method is to 
protect the usefulness and longevity of existing 
antimicrobials, while continuing research into new 
vaccines, drugs, and related technologies, for much is still 
to be learnt about the mechanisms of infection and 
resistance.2 The starting point for any concerted policy 
action should be to expand access to life-saving 
antimicrobials worldwide, recognising that some parts of 
the world still face issues of poor sanitation and inadequate 
access to antimicrobials.3 However, expansion of access 
needs to be linked to improved approaches for combating 
resistance. Evidence shows that many interventions can 
be eff ective at national levels,4 but their implementation 
also requires global vigilance and action.
Coordination across sectors is necessary to preserve 
antimicrobial eff ectiveness. Gains in combating resistance 
through health-care interventions might be undercut by 
prolifi c use in agricultural settings. Strong conservation 
eff orts, although medically appropriate, might hamper the 
business case for innovation that leads to new therapies. 
Boosting access without stewardship measures could 
drive resistance. Thus, although many actions can be 
taken independently at the national and sectoral levels, 
they will be more eff ective if coordinated globally across 
all relevant sectors and stakeholders.5
The complex policy challenges of improving access to 
and sustaining eff ectiveness of antimicrobials warrant 
interventions in several areas. This Lancet Series has used 
a framework spanning the breadth of policy goals 
needed.4 Improved surveillance and monitoring are 
crucial to obtain information on the present situation and 
progress.4 Universal access to antimicrobials needs to be 
a primary goal in all countries progressing towards 
universal health coverage.3 However, the need for 
antimicrobials can be lessened through improved 
infection control, and their use can become more 
appropriate by reducing misuse and overuse through 
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Key messages
• Global collaboration is necessary to improve access to antimicrobials and sustain their 
eff ectiveness. Although this is well known and accepted, present collaborative eff orts 
remain far too modest and poorly funded.
• Interlinked global collaboration is needed in the policy areas of universal access, 
responsible use, and innovation. Increasing innovation and global access without 
responsible use provisions might increase the emergence of resistance. Strengthened 
eff orts towards responsible use could lead to smaller and less lucrative markets, thus 
dampening innovation and possibly impeding access. To avoid improper incentives 
to waste antimicrobials, payments for antimicrobials should be delinked from the 
volumes sold.
• WHO cannot successfully tackle this problem on its own. Because of the multisectoral 
nature of the problem—requiring action across the health, agriculture, and veterinary 
sectors—and the need to build new business models for antimicrobial innovation and 
use, multisectoral coordination under a One Health model is necessary to bring about 
action and real change.
• Global actions to address this challenge need to be a combination of quick wins and 
long-term eff orts. For example, a few large markets could agree to restrict certain 
classes of antimicrobials only to human use while a formal global mechanism is being 
negotiated and adopted. This combination of short-term and long-term strategies 
needs to be taken for each policy area—namely, surveillance, universal access, 
infection prevention, responsible use, and innovation.
• Global coordination and fi nancing mechanisms need to be improved. Two leading 
institutional options are a new UN-level coordinating body and an international 
treaty with strong implementation mechanisms.
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interventions that decrease both supply and demand.3,4 
Progress towards these goals will rely on raised awareness 
among the public and all relevant stakeholders (eg, policy 
makers and health-care personnel).4 Advances also need 
to build on an expanded knowledge base, through 
innovation and research and development (R&D), to 
achieve an increased understanding of mechanisms and 
drivers of resistance,2 develop new technologies,3 and 
design, implement, and assess interventions.4 The control 
and reduction of resistance are public goods—ie, 
achievements in which all stand to benefi t. However, with 
increasing antimicrobial resistance in low-income and 
middle-income countries (LMICs),1 these nations will 
struggle to fi nance the implementation of these policies, 
and fi nancial assistance will be key to global success.
In this last paper of the Series, we analyse how countries 
and other stakeholders need to work together to achieve 
these key policy goals. We identify existing gaps in 
international cooperation, recommend actions to improve 
collaboration, and discuss how the resulting policies 
could be packaged for adoption and imple mentation.
Strengthening international collaboration
We reviewed all World Health Assembly resolutions and 
documentation related to antimicrobial resistance, in 
addition to related scientifi c literature published in 
2012–15, to identify core high-level policy areas—namely, 
surveillance, universal access, responsible use, infection 
control, and innovation. Improved imple mentation 
across these policy areas is needed to ensure sustainable 
access to eff ective antimicrobials. Together with the 
other papers in this Series,1–4 we identifi ed important 
gaps in international collaboration in each of the fi ve 
policy areas (panel). However, the level of collaboration 
necessary to ensure success will diff er from policy to 
policy. On the basis of the 5C Framework (fi gure), 
previously used to analyse human resources for health,6 
we assessed the minimum level of collaboration needed 
for a policy to achieve its goal and the relevant 
international policies (table 1).
Some global policy objectives can be met by 
collaborative mechanisms that help to set common 
norms, principles, and goals. This is the lowest level of 
collaboration in the 5C Framework, one that is often 
eff ectively fulfi lled by UN entities and exemplifi ed 
by WHO’s resolutions on antimicrobial resistance.1 
However, higher levels of collaboration are necessary for 
other objectives. For example, another function of WHO 
is to facilitate communication, which includes sharing 
of information and data between countries—eg, 
dissemination of guidance and educational material on 
appropriate disease management and treatment 
regimens.3 Coordination is essential for eff ective global 
surveillance systems and for the uptake of adequate 
infection control procedures.3,4 Other objectives—eg, 
promotion of universal access, responsible use, and 
innovation—will need even higher levels of collaboration, 
including collaborative decisions and, at the highest 
level, collective action (fi gure). Such international 
collaboration is necessary to ensure the success of many 
policies that improve access to and sustain eff ectiveness 
of antimicrobials (table 1).
Surveillance
Two related issues of surveillance are collection and 
reporting of data, and strengthening of laboratory 
capacity. WHO fi rst passed a resolution in 1998 urging 
Member States to develop surveillance systems for 
antimicrobial agents.7 Despite the WHO global strategy 
for containment of antimicrobial resistance (2001) and 
recurrent calls to improve these global surveillance 
eff orts, little progress has been made in the past 15 years.8 
Worryingly, the fi rst antimicrobial resistance global 
report on surveillance (2014) of existing national systems9 
showed that only 22 countries were able to report on all 
nine bacterial species of international concern. However, 
114 of the 129 countries who reported their status 
obtained data for at least one species.
Panel: Gaps in international collaboration
• Surveillance—no global database exists for antimicrobial 
resistance or use, meaning that identifi cation of 
surveillance gaps is diffi  cult or impossible. No publicly 
available registry of laboratory capacity by country exists. 
Surveillance data are rarely recorded in real time or 
globally compatible in format.
• Infection control—a common repository for evidence of 
infection prevention measures is absent. Substantial 
fi nancing and technical assistance is needed to help 
low-income and middle-income countries (LMICs) to 
implement evidence-based national infection 
prevention programmes.
• Universal access—no internationally agreed mechanisms 
exist to ensure aff ordability in LMICs. Financing to 
support improved access to antibiotics is restricted.
• Responsible use in human beings—the framework to 
restrict marketing of antimicrobials has not been agreed. 
Capacities to enforce existing regulations are insuffi  cient, 
and no internationally agreed quality measures for 
optimum prescribing exist.
• Responsible use in animals—no global mechanisms exist 
to reduce inappropriate use in animal husbandry or 
restrict specifi c classes to human use only. Europe is the 
only region that have banned the use of antibiotics in 
livestock and agriculture as growth promoters or for 
disease prevention.
• Innovation—existing incentives are not well aligned to 
responsible use policies. The bulk of these initiatives were 
not developed with the needs of LMICs in mind. The scale 
of these initiatives is insuffi  cient to ensure the 
development of new antimicrobials, diagnostics, vaccines, 
or related technologies that target unmet medical needs.
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To comply with the International Health Regulations 
(IHR; 2005), each government is required to have access 
to laboratory services and obliged to report to WHO.10 At 
the WHO Executive Board Meeting in January, 2014, 
only 23 Member States were reported to be fully 
compliant with the IHR’s laboratory requirements.11 
This self-reporting shows that many Member States, 
across all income categories, are struggling with the 
laboratory capacities stipulated by the IHR. Since these 
capacities are more comprehensive than those necessary 
for antimicrobial resistance surveillance, the actual 
magnitude of inadequate laboratory capacity directly 
related to antimicrobial resistance is unknown at 
present. In 2011, three UN agencies—WHO, World 
Organisation for Animal Health (OIE), and the Food and 
Agriculture Organization (FAO)—jointly initiated 
several collaborative projects that aimed to strengthen 
laboratory capacity. These projects included capacity 
building for compliance with laboratory quality 
standards, the development of international networks, 
and laboratory twinning initiatives.12
A global surveillance system is essential to improve 
access to and sustain the eff ectiveness of antimicrobials.4 
The communication of surveillance data can help to 
identify patterns of resistance and focus on necessary 
support. This is not a call for a new global super system 
but rather a coordinated eff ort to obtain data from 
present functioning systems, implement appropriate 
systems in countries without existing ones, report these 
data, and highlight the gaps annually. These data 
include the use of antimicrobials (in human beings and 
livestock, and for other agricultural purposes), the 
prevalence of antimicrobial resistance, and laboratory 
capacity, all by country, in a standard way so that valid 
comparisons can be made. This coordination will 
require cross-sectoral focus bridging the FAO, OIE, and 
WHO. To accurately report prevalence data, national 
and regional laboratory capacity has to be strengthened. 
Capacity-building plans, including technical and 
fi nancial support, should be created for countries that 
are unable to report these data. As this function matures 
and as countries improve their reporting, interoperability 
and minimum data standards can be implemented.
Infection control
Many infection control collaborations are at work across 
the globe through local, national, regional, and 
international networks, as detailed by Dar and colleagues 
in this Lancet Series.4 However, many of these collaborations 
are underfunded. LMICs are lagging behind high-income 
countries, predominantly because of inadequate fi nancial 
resources necessary for good infection control.13
National infection prevention programmes are the 
mandate of governments, but external supportive 
fi nancing of these eff orts in LMICs should continue. 
These eff orts should be linked to surveillance data so that 
those countries reporting increasing resistance levels or 
inappropriate use can receive technical and fi nancial 
assistance to reverse these trends. On a global basis, it 
might be more effi  cient to speed the adoption of basic 
Figure: The 5C Framework—assessment of minimum collaboration needed for a successful policy
This framework can be used to assess the minimum level of collaboration needed for a policy to deliver its stated goal. It is hierarchical—ie, level V (collective action) 
requires greater collaboration than level IV (collaborative decisions) and so on. 
To what extent does the policy require binding multinational
decisions (eg, through joint institutional arrangements
or pooled financing)?
To what extent does the policy require multinational
collaborative decision making (eg, through joint strategies)?
To what extent does the policy require coordination
of individual countries’ decision making?
To what extent does the policy require effective
sharing of information and data?
To what extent does the policy require common
norms, principles, and goals to be shared and agreed
across organisations and governments?
V
Collective
action
IV
Collaborative
decisions
III
Coordination
II
Communication
I
Common norms, principles, and goals
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infection prevention measures than to create new drugs 
that are short-lived. Evidence of eff ective infection control 
interventions is a global public good and should be 
made readily available, including summaries appropriate 
for policy makers.4
Universal access
Securing access to quality-assured antimicrobials is a 
core national responsibility, and policies that countries 
can use to improve access are discussed by Mendelson 
and colleagues in this Lancet Series.3 The coordinated 
Level of cooperation—5C assessment
Surveillance
Develop mechanisms for 
surveillance data collection 
and reporting
Communication (level II)—surveillance information needs to be shared internationally. Eff orts have already been attempted with 
common norms, principles, and goals. Each of the four WHO resolutions from 1998 to 2014 has urged Member States towards 
heightened surveillance.
Coordination (level III)—a global agreement on an international data collection mechanism is needed to ensure that countries are 
tracking key drug–bug combination data and using common standards. With a global system, countries that are yet to achieve fully 
developed monitoring systems can be rapidly identifi ed and off ered assistance. As this reporting process matures, interoperability 
and reporting standards will become important. Surveillance data will need to be centrally stored, analysed, and monitored for 
gaps. Data should have the potential to be aggregated to allow for meaningful analyses of resistance on a large scale, and a 
cross-sectoral focus bridging FAO, OIE, and WHO is necessary.
Build laboratory capacity and 
implement regionally
Coordination (level III)—donors and governments need to jointly prioritise fi nancing and technical capacity building to improve 
national and regional laboratories. For countries without suffi  cient laboratory capacity, at a minimum, a plan should be developed 
and fi nanced to off er either a national or a regional solution. WHO has been delivering on common norms, principles, and goals of 
best practices for laboratories and communicating these to Member States. Two of the four WHO resolutions urge Member States 
to improve laboratory capacity building. A higher level of collaboration is needed.
Infection control
Finance and generate 
evidence of infection 
prevention and control 
interventions
Communication (level II)—evidence of eff ective interventions is a global public good to be shared, summarised, and promoted to 
stakeholders and policy makers.
Coordination (level III)—LMICs might need fi nancial assistance to implement suffi  cient interventions. Donors need to jointly 
prioritise the fi nancing of eff ective infection prevention measures, such as improved hygiene practices and immunisation, for 
countries with few fi nancial resources.
Universal access
Ensure that eff ective 
antimicrobials are equitably 
accessible
Coordination (level III)—donors and governments need to jointly prioritise universal access to antimicrobials as a basic step 
towards achieving universal health coverage. Insuffi  cient access in LMICs is a market failure and requires corrective action, such as 
the international assistance (both fi nancial and technical) provided through the Global Fund to Fight AIDS, Tuberculosis and 
Malaria.
Collaborative decisions (level IV)—strengthening of health services and systems to provide universal access to antimicrobials needs 
to happen at the national level. However, global-level facilitators are needed to ensure aff ordability in LMICs.
Responsible use in human beings
Develop mechanisms for 
responsible marketing, sales, 
and use
Collaborative decisions (level IV)—although regulations are a national responsibility and prerogative, the global market of 
antimicrobials crosses many borders. As a result, common standards and practices that are regularly communicated are necessary. 
These internationally agreed policies could take the form of either self-regulatory codes of practices or a binding legal agreement.
Coordination (level III)—although the regulation of medical practice is a core national responsibility, information on best practices 
for responsible use should be created and shared broadly, with appropriate adjustments showing available resources in the 
health system.
Responsible use in agriculture
Restrict specifi c classes of 
antimicrobials to human 
use only
Collaborative decisions (level IV) or collective action (level V)—each country will need to pass eff ective laws to implement these 
restrictions. In the short term, incentives could be given to patent holders and generic-drug producers, rewarding them for sales 
restriction. Global enforcement of this policy necessitates either collaborative decisions or collective action. This policy will only be 
successful if it is consistently implemented and regulated worldwide.
Reduce the use of antibiotics 
for growth promotion and 
disease prevention in animals
Collaborative decisions (level IV) or collective action (level V)—although each country needs to determine how it will reduce the 
use of antibiotics for growth promotion, collaboration is needed to ensure that the reduction is sizeable enough to make a 
diff erence and to avoid free riding. Global collective action is probably the best way to avoid free riding in countries where 
antimicrobial misuse continues. To be eff ective, compliance incentives or penalty for countries, perhaps through a global legal 
instrument, are necessary.
Innovation
Finance priority R&D that is 
stipulated on responsible use 
provisions
Collaborative decisions (level IV) or collective action (level V)—R&D costs are larger than those bearable by any one country, but 
substantial progress could be made with leadership from groups such as the G7, G20, and BRICS. Collaboration on both fi nancing 
and R&D activities is necessary. Usually, fi nancing could be done through governmental coordination (level III); however, the 
allocation of this fi nancing for new antimicrobials, vaccines, and diagnostics should be bound to restrictions that promote 
responsible use and therefore require enforcement, meaning that a higher level of collaboration (ie, level IV or V) is necessary. New 
business models that delink innovation from the volume of sales and unit prices might necessitate collective action, at least by a 
core group of countries that bear the major share of R&D costs.
Since we have selected what we believe is the minimum level to drive change, higher levels could also be adopted and be just as successful. FAO=Food and Agriculture 
Organization. OIE=World Organisation for Animal Health. LMICs=low-income and middle-income countries. R&D=research and development. BRICS=Brazil, Russia, India, 
China, and South Africa. 
Table 1: Policies that require international collaboration
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eff orts of organisations such as The Global Fund to Fight 
AIDS, Tuberculosis and Malaria, Unitaid, and the US 
President’s Emergency Plan for AIDS Relief (PEPFAR) 
have greatly contributed to improved access to specifi c 
antimicrobials. However, antibiotics, diagnostics, and 
related prevention measures mostly fall outside the 
mandate of these organisations. Most fi rst-line antibiotics 
are inexpensive, costing only pennies per treatment 
regimen. However, with the emergence of resistance, the 
cost ramps up substantially as second-line and third-line 
drugs are needed.14 Donors and governments need to 
prioritise universal access to aff ordable and eff ective 
antimicrobials as a key part of a comprehensive global 
solution, thereby contributing to progress towards 
universal health coverage.
Many untested alternatives to tackle the issue of anti-
microbial access will need to be carefully balanced 
against economic incentives for innovation. One option 
is for manufacturers to sell their products globally at cost 
price while receiving rewards (eg, so-called benchmark 
payments) from high-income countries. These payments 
would not be tied to unit sales but to compliance with 
stipulations such as no promotional marketing of the 
product, sales levels in compliance with responsible use 
estimates in both human and animal populations, and 
equitable access. Another option could be that 
manufacturers off er nominal-royalty-bearing licences to 
other manufacturers in LMICs, with similar conditions 
on the licensees. A third option is to establish 
internationally agreed principles related to securing 
aff ordability in low-income countries, where price levels 
should be based on what can be achieved by competitive 
manufacturing. All of these options will need decisions 
that are made in collaboration across countries, with 
substantial fi nancial support to promote universal access.
Responsible use in and for human beings
Most countries have regulations to ensure drug quality 
and responsible marketing, sales, prescriptions, and use 
of pharmaceuticals. In paper 4 of this Series, Dar and 
colleagues4 have provided specifi c examples of how these 
regulations can be strengthened and incentives aligned, 
including solutions targeting prescribers and reducing 
over-the-counter sales. However, an international 
consensus is needed to sustain the global eff ectiveness of 
antimicrobials. A potential solution for responsible 
marketing and sales is a voluntary, self-regulatory code of 
practice by all manufacturers to restrict marketing and 
provide transparency on sales and consumption. If such 
an international self-regulatory mechanism fails, then 
intergovernmental agreements might be necessary. 
However, this approach addresses only one side of the 
issue. At the same time, physicians should be incentivised 
to adhere to clinical guidelines. Regulations and systems 
should be strengthened to reduce or eliminate 
over-the-counter sales without evidence of appropriate 
diagnosis. The existence of over-the-counter antibiotics is 
justifi able only as a short-term solution in low-income 
settings with poor access to health-care professionals or 
others who could guide responsible use. Ensuring access 
to eff ective antimicrobials, like most other health 
priorities, requires a functioning health-care system.
To change professional behaviour, best practices in the 
prescribing and use of antimicrobials should be easily 
and freely accessible worldwide. Although these 
practices, rooted in evidence and surveillance data, are 
global public goods, they are time-consuming and 
expensive to create and disseminate. This is not to say 
that global guidelines on antimicrobial use are desirable; 
rather, adjustments need to be made for the national 
epidemiological context and resistance profi le. However, 
global guidance for best practice guidelines should be 
coordinated with full transparency.
Some antimicrobials are so medically important that 
strong actions such as enforcement mechanisms need 
to be taken to ensure their continued eff ectiveness. 
One example is possible limits on over-the-counter sales 
of critical classes such as carbapenems. For these drugs, 
an option is to learn from the positive experiences 
(and avoid the negative results such as those related to 
challenges to access) of the controlled drug regimen, 
which is rooted in international treaty commitments.15,16 
More analyses are needed to explore what aspects of 
such an approach can be adopted and what aspects will 
need adaptation.
Responsible use in agriculture
Antibiotics are important in treatment of disease in both 
human beings and animals, but they are also being used 
in healthy animals as growth promoters and a substitute 
for good animal husbandry.1,4 In view of the devastating 
potential of antimicrobial resistance, all unnecessary use 
needs to be curbed. FAO, OIE, and WHO have the 
responsibility to raise awareness in their respective 
fi elds regarding maintenance of eff ective antimicrobials, 
with WHO having the primary mandate to articulate the 
public health need for urgent and sustained action. A 
need exists for a global agreement on responsible animal 
use by elimination of antibiotics used as growth 
promoters or as a routine prevention tool through herd 
treatment. Global collaboration and enforcement are 
necessary to ensure a level playing fi eld, since reductions 
in access to antimicrobials might have implications on 
the running costs of a farm—eg, more oversight of 
livestock might be needed.1 Europe banned the use of 
antibiotics for growth promotion in 2006.17 The USA 
introduced non-compulsory measures in 2013, which 
have now resulted in binding withdrawals and label 
changes.18 The Chennai declaration aims to achieve an 
80% compliance with the rule that antibiotics used for 
human treatment will not be used for growth promotion 
in food animals.19 In exchange for these prohibitions, 
R&D related to animal-specifi c solutions, such as 
vaccines and alternatives to antibiotics as growth 
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promoters, should be encouraged. While these 
agreements are being negotiated and implemented, a 
medium-term solution could be labelling suggestions to 
producers that are already adhering to the best practices. 
These foods could command higher prices, similar to 
those of organic or local foods. Several major US 
restaurant chains are already transitioning to use 
chicken and other meats produced without antibiotics 
used in human beings.20
International trade law can be an obstacle to reduce or 
eliminate the use of antibiotics as growth promoters or 
for routine preventive herd treatment, since a formal 
national requirement to regulate or ban such use of 
antibiotics might be interpreted as a trade barrier 
through the World Trade Organization (WTO) rather 
than a public health measure.21 Therefore, WTO and 
regional trade agreements need to be engaged to ensure 
that necessary public health regulations related to 
antimicrobial resistance are respected.
Another option is to restrict medically important 
antimicrobials to human use only, leaving other classes, 
such as ionophores, exclusive to agricultural use. For 
example, to begin the process towards reaching a global 
consensus, the G20 countries could develop an 
agreement in which certain classes of new antimicrobials 
and other related health technologies are restricted for 
use in either human beings or animals, and incorporate 
this agreement into future trade agreements. This 
agreement could be coordinated through the Inter-
national Conference on Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for 
Human Use (ICH), a collaboration between the 
pharmaceutical industry and the regulatory authorities of 
Europe, Japan, and the USA.22 A potential result is that 
pharmaceutical manufacturers and animal feed providers 
would be less interested to produce an animal variety for 
the non-participating countries not only for reputational 
reasons but also for the limited profi tability of the 
remaining markets. Additionally, innovation incentives 
for companies could be conditioned on compliance with 
these rules in every country. Once compliance exists in 
ICH, it could be transitioned to the more comprehensive 
International Conference of Drug Regulatory Agencies 
organised by WHO.
Innovation
Sustainable access to eff ective antimicrobials requires 
constant innovation, if only to prevent us from slipping 
back into a pre-antibiotic era.23 The largest multinational 
fi nancing initiative so far for antimicrobial R&D is the 
Innovative Medicines Initiative (IMI), a public–private 
partnership between the European Union and the 
European pharmaceutical industry that aims to develop 
better and safer drugs. Its New Drugs for Bad Bugs 
(ND4BB) programme has invested more than 
€600 million in European antimicrobial R&D over 
7 years, much of which has been targeted at 
Gram-negative bacteria.24 The European Union’s Joint 
Programming Initiative on Antimicrobial Resistance 
(JPIAMR) aims to fi nd routes for novel antibiotics and 
new anti-infectious disease strategies. Their fi rst call, 
“InnovaResistance”, with a total budget of around 
€14 million, was launched in January, 2014, and included 
funding opportunities for optimisation of existing 
antimicrobials and identifi cation of new bacterial targets 
and antibiotic compounds.25
Several national initiatives are of a magnitude to have a 
global eff ect, even though their geographical scope is 
restricted. An announcement in June, 2014, stated that 
the £10 million Longitude Prize would focus on 
point-of-care diagnostics, with the creation of a 
“cost-eff ective, accurate, rapid and easy-to-use test for 
bacterial infections”.26 A similar diagnostic prize 
proposal was announced by the US Government in 
September, 2014.27 Some countries have also created 
partnerships with individual pharmaceutical companies; 
one such example is the 3·5-year collaboration between 
AstraZeneca and Singapore’s Agency for Science, 
Technology and Research to develop new drugs against 
Gram-negative bacterial infections.28 The Biomedical 
Advanced Research and Development Authority 
(BARDA) in the USA has partnered with GlaxoSmithKline 
(GSK) to develop new antibiotics with a potential of 
US$200 million for GSK if milestones are met.29 Total 
funding from the US National Institutes of Health for 
antibacterial resistance averaged US$90 million per year 
in 2013 and 2014.
Although an increasing investment is seen in relevant 
R&D, present initiatives are still insuffi  cient to ensure 
the continued development of new antimicrobials, 
diagnostics, or related technologies.30 Most distressingly, 
these initiatives are not tied to responsible use policies. 
In particular, the existing R&D system closely links 
incentives for R&D to the potential price and volume of 
sales of the eventual product.3 This system leads to 
underinvestment in antibiotic research, high eventual 
prices for new products, and lacklustre company support 
of antibiotic stewardship.31 There is little assurance that 
the new drugs will not be wasted through inappropriate 
use. This market failure could be addressed by eff orts to 
delink company profi ts from the sales volume for 
antimicrobials.30 Since it is a problem that aff ects all 
countries, including those with the fi nancial means to 
fi x it, it should be solvable. Complete global action is 
not necessarily required because the actions of a few 
high-income countries can have a disproportionately 
large global eff ect, and additional countries will join the 
eff ort in due course.
Therefore, a pledge from a group such as the G20 to 
increase their investment in R&D tied to responsible 
use and global access stipulations could have a 
substantial eff ect on the antimicrobial R&D landscape. 
The new products should be tied to responsible use 
provisions to minimise the development of resistance,32 
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which would probably include agreement by 
manufacturers to not promote the products in exchange 
for payments that are not based on unit sales. Moreover, 
the innovators would need to ensure that their new 
products are globally available, as discussed in the 
section on universal access. These stipulations would 
be negotiated and enforced contractually between 
innovators and high-income countries.
Subobjective National level Global level
Access
Expand access Increase availability, 
aff ordability, and 
diagnostic targeting of 
eff ective antimicrobials
To achieve appropriate antimicrobial prescribing, LMICs should expand access 
to appropriate antimicrobials, especially in rural areas, including provision of 
laboratory support and increased access to diagnostics
Global universal access demands a long-term commitment, 
with sustained fi nancing for all aff ected countries
Responsible use
Reduce inappropriate 
use
Change professional 
behaviour
Stewardship programmes can be eff ective in encouraging appropriate use of 
antibiotics and should be scaled up in both HICs and LMICs where feasible
Global guidance should be rooted in evidence and 
surveillance data as templates for adaptive national 
guidelines on antimicrobial use
Increase public 
awareness
Change public expectations Public awareness campaigns can be eff ective when sustained and properly 
adapted for local contexts; national campaigns should be encouraged
Global campaigns should be evidence based and their 
results assessed
Reduce inappropriate 
use in animals
Regulate inappropriate use 
or incentivise appropriate 
use
Antibiotic use for growth promotion or prophylaxis in animals should be 
reduced or eliminated; these policies should be coupled with adequate 
investment in improved IPCIs in livestock and for other agricultural uses, and 
with eff ective mechanisms to remunerate veterinarians and prescribers while 
limiting their ability to profi t from antimicrobial sales and reorienting their 
roles away from commercial gains; further research into the implications of 
this policy in LMICs is needed
A coalition of key countries can lead the way to restrict 
specifi c classes of antimicrobials for human use only; 
countries should work with WTO to transition away from 
the use of antibiotics for growth promotion or prophylaxis, 
using health and SPS exceptions under trade agreements
Infection control
Reduce need for 
antimicrobials
Strengthen infection 
control
Implementation of eff ective IPCIs needs to be supported, including 
vaccinations, hand hygiene, improved access to water and sanitation, food 
safety, and behaviour change
IPCIs have chronic underfunding, particularly in the animal 
sector, and an investment of several billion US dollars per 
year is necessary to upgrade capacity in most LMICs; 
global standards for reporting of infections and training of 
health workers on hand hygiene and infection control 
should be introduced
Innovation
New knowledge (R&D) New antibiotics, 
diagnostics, vaccines, and 
other relevant technologies
National policies should work in concert with global framework eff orts, as 
antibiotic R&D is a global endeavour
A coalition of key countries can initiate eff orts that will 
have global results, but investments in new antibiotics 
should decouple the price from units consumed, so that 
responsible use can be built into the reimbursement and 
use of diagnostics
New knowledge (R&D) Increased innovation to 
meet the needs of LMICs
National-level research is needed to understand the particular needs of LMICs 
with regards to bacterial resistance, such as a rapid point-of-care diagnostic 
test that can improve clinical practice in low-resource settings
For antimicrobials, the general recommendations 
(including delinkage) of WHO’s Consultative Expert 
Working Group on Research and Development: Financing 
and Coordination should be acted on
Surveillance
Improved monitoring Infections and outcomes, 
and antimicrobial use; 
environmental 
surveillance; drug quality
Countries and regions should adopt surveillance systems that best suit their 
needs and circumstances, and a programme of harmonisation and 
integration of global systems needs to be fostered so between-country 
comparisons of antibiotic use and resistance can be more meaningful; the 
sentinel surveillance of environmental settings that are likely to contribute to 
resistance should be initiated and expanded in HICs and its feasibility 
explored in LMICs; for LMICs, an additional focus is to improve monitoring of 
drug quality to curb the production of substandard and counterfeit drugs
Establish a global surveillance system to annually obtain 
data for and report on the use of antimicrobials and the 
prevalence of resistance by country, including eff orts to 
strengthen laboratory capacity, in both human and animal 
populations; LMICs might need fi nancial support in these 
pursuits; this will also help with a global threat assessment 
of risks from antimicrobial resistance
Integration across the policy areas 
Evidence base None National research programmes need to address unanswered questions and 
research gaps, including how to minimise selection of resistance, secure quality 
of existing drugs, eff ectively reduce the prevalence and transmission of 
resistant pathogens, and better understand the basic mechanisms of resistance
Systematic reviews of existing policies are needed across 
human, animal, and environmental health and the key 
areas of resistance control; a standardised framework for 
policy examination should be applied and an open-access 
central repository of national, regional, and global policy 
case studies and assessment developed
Coordination None Not applicable Better global coordination and fi nancing mechanisms are 
required—eg, informal country coalitions, a pan-UN 
intergovernmental agency, or an international treaty
LMICs=low-income and middle-income countries. HICs=high-income countries. WTO=World Trade Organization. SPS=sanitary and phytosanitary. IPCIs=infection prevention and control interventions. 
R&D=research and development.
 Table 2: Overall recommendations for policy interventions
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The global action plan to combat antimicrobial 
resistance
In this Lancet Series, we have identifi ed a set of 
recommendations across the fi ve policy areas both for 
individual countries and globally (table 2). Each one of 
these policy recommendations could be implemented 
individually but might work at cross purposes to each 
other as we have described. To create an eff ective and 
sustainable path forward, these recommendations 
should be implemented in concert.
At the 68th World Health Assembly in May, 2015, a 
global action plan to combat antimicrobial resistance was 
approved by Member States.33 This global action plan 
provides the framework for national plans to combat 
antimicrobial resistance, in which Member States need to 
defi ne timelines, targets, and activities, and identify 
particular areas that need technical support from WHO 
and other partners. Successful implementation depends 
on Member States playing their crucial part to fulfi l 
commitments, mobilise funding, implement appropriate 
surveillance programmes, build and support the necessary 
infrastructure (eg, laboratories), and introduce and 
enforce appropriate legislation.
The global action plan also gives WHO a clear 
mandate, leadership, and coordinating role, since WHO 
represents a natural platform for global health solutions 
that require improved communication and coordination 
among countries, including those of surveillance, 
infection control, and guidance on stewardship 
(table 1).3,4 Although many of the needed global actions 
have long been recognised, implementation by Member 
States, WHO, or other actors has been insuffi  cient. A 
report from the WHO Secretariat concluded that past 
World Health Assembly resolutions, reports, and calls 
for mobilisation have not resulted in widely accepted 
global actions.34 This inertia could probably be explained 
by various reasons—eg, insuffi  cient fi nancing, strong 
lobbying on behalf of diverse stakeholders, free-riding 
tendencies, and so on. Progress depends on convincing 
individual countries of the eff ect of local actions, and 
fi nding suitable solutions and the necessary support in 
this endeavour.3,4
National accountability and indicators
The great diff erentiator between the global action plan 
and past WHO resolutions has to be strong national 
accountability mechanisms to ensure that Member 
States create and implement their own plans to combat 
antimicrobial resistance. These mechanisms are likely to 
be a mixture of incentives and enforcement measures 
based on measurable indicators. For LMICs, external 
fi nancing might be predicated upon development of a 
national plan to combat antimicrobial resistance and 
eventually report against a set of agreed indicators. 
Compliance to national plans can be reinforced by widely 
reporting results in plain language so that local media is 
engaged in national progress (see table 3 for examples of 
national indicators).
WHO’s South-East Asia Region is to be commended 
for developing its own indicators in 2010.35 Whereas this 
policy-oriented approach uses process indicators, we 
suggest data-driven targets, such as annual per-person 
antibiotic consumption, so that the indicators do not 
need to change when new national goals are proposed. 
Almost all of our suggested indicators (table 3) report 
against several policy areas. For example, annual 
per-person antibiotic consumption can report progress 
both in a country with insuffi  cient access to antibiotics 
and in a country with overuse of antibiotics, showing that 
interlinkages exist between the policy areas.
Even though we suggest only six indicators, we 
believe that few countries can report on all six of them 
at present. Improved surveillance systems will need to 
be implemented; although such systems are costly and 
time-consuming, they are a precondition to establish 
accountability. For low-income countries, such systems 
Indicator Rationale
Surveillance IHR’s existing laboratory indicator (ie, Laboratory services) is 
available to test for priority health threats
Identify laboratory capacities that need improvement, including 
external resources
Surveillance and access Annual antibiotic consumption by drug and age Match against national goals to suggest change in antibiotic 
consumption in specifi ed populations
Surveillance and infection 
control
Annual incidence of antimicrobial resistance by pathogen and 
age (ie, a national threat assessment)
Identify which pathogens are being tracked and progress towards 
controlling the emergence of resistance over time
Surveillance and 
responsible use
Annual percentage of total antibiotic consumption in human 
use and agriculture by drug; in agriculture, report by animal 
species, drug, and purpose
Quantify the split of antibiotic consumption between human and 
non-human use, and reduce non-human use
Surveillance, responsible 
use, and access
Annual consumption of restricted-use antibiotics Show the overconsumption or underconsumption of antibiotics 
deemed to be of critical medical importance
Innovation and access New molecular entities submitted to and approved by 
regulatory authorities, by therapeutic area per year, with a 
focus on drugs targeting priority pathogens identifi ed 
through threat assessments
Compare trends in global innovation of new antimicrobials, 
vaccines, and diagnostics, and access to these innovations 
in LMICs 
IHR=International Health Regulations. LMICs=low-income and middle-income countries.
Table 3: Potential national indicators in the WHO global action plan, by policy area
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might require long-term fi nancing commitments from 
donors, tied to measurable results and careful 
incremental and scalable implementation, potentially 
starting fi rst with public hospitals and clinics and 
expanding from there.
A coherent package of solutions
These interlinkages between policy areas complicate 
implementation, since each of the areas requires real 
eff ort for some actors, thereby blocking unanimous 
support. In other cases, benefi ts for individual groups of 
actors are insuffi  cient to warrant unilateral action. 
Among the fi ve policy areas considered in this Series, we 
have shown that three—namely, access, responsible use, 
and innovation—will need collaborative global decisions 
or collective global action (table 1). We believe that the 
best way forward towards an international agreement 
on these three policy areas is not to tackle them 
independently but as one coherent package. These policy 
areas should be linked to deliver a sustainable and 
cost-eff ective solution—eg, by substantially increased 
coordination of public sector R&D funding and incentives 
for innovation, both tied to stipulations of minimal 
marketing and to licensing intellectual property to 
manufacturers in LMICs who are also bound by 
responsible use provisions.
If the coherent package is constructed carefully, most 
of the diverse range of stakeholders will benefi t from a 
long-term solution securing eff ective antimicrobials 
(table 4). High-income countries will need to pay most of 
the innovation bill but will, in return, protect their 
populations from infections that cross borders. More 
equitable access will be achieved for all countries in 
return for better infection control and stewardship. 
Low-income countries will get support for capacity 
building and be assured aff ordable and appropriate 
antimicrobials. R&D-based pharmaceutical companies 
will receive higher and more predictable rewards for 
antimicrobial innovations than they do at present, and 
generic-drug manufacturers will have opportunities to 
produce quality-assured drugs under licence. Restrictions 
in antibiotic use in agriculture will promote global fair 
competition, since all producers have to abide by the 
same public health measures, supported by research for 
alternatives to agricultural antibiotics.
Achieving collective action
The responsibility to implement this coherent package 
needs to rest on suffi  ciently funded and empowered 
authorities. An institutional base and a forum for 
negotiation are necessary to ensure progress. WHO 
alone will be unable to facilitate the implementation of 
this package, and a multisectoral response—eg, from a 
UN-appointed entity or one structured through a 
coalition of like-minded, proactive countries and actors—
will be essential. Such a response can be rooted in 
international law or be an institutional solution 
originating from a top-level political declaration. An 
internationally binding agreement could be the end 
result after substantial momentum is achieved in 
national implementation.
An international legal mechanism can be negotiated at 
WHO or the UN General Assembly. One weakness of a 
treaty is the need to cover most or all nations through an 
Benefi ts Costs
All countries Greatly improved global health; avoidance of the costs of a 
post-antimicrobial era (eg, inability to perform routine 
surgeries and treat common infections); avoidance of the 
inevitable closure of borders and restraints on travel and 
trade that would follow from rampant epidemics
Increased investments to protect and sustain 
eff ectiveness of antimicrobials
LMICs Enhanced access to aff ordable antimicrobials, including 
subsidised prices when necessary; fi nancial and technical 
support for capacity strengthening in surveillance, 
responsible use, and infection control
Increased investments in health system capacities for 
surveillance, responsible use, and infection control
Emerging economies Increased markets for producers of antimicrobials Increased investments in and enforcement of regulatory 
capacities, and investments in health system capacities 
for surveillance, responsible use, and infection control
High-income countries Sustainability of existing antimicrobials and the medical 
care system that depends on them
Increased investments in innovation through R&D and 
aggregate reimbursement or delinked payments to 
producers; support to LMICs for capacity building
Innovative pharmaceutical 
companies
Increased rewards and incentives for innovation; decreased 
marketing expenses; reduced risk and structured rewards 
through delinked payments
Adherence to additional marketing regulations and 
cooperation on global public health goals
Generic pharmaceutical companies Opportunity to manufacture antimicrobials on licence 
for LMICs
Adherence to additional marketing regulations, quality 
assurance, and other stipulations
Agriculture A level playing fi eld with global regulations regarding 
antibiotic use in agriculture, especially for meat production
Increased investments in animal health and welfare, 
including alternatives to antibiotics
R&D=research and development. LMICs=low-income and middle-income countries.
Table 4: Benefi ts and costs accrued by a coherent package
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opt-in instrument that needs ratifi cation by Member 
States to become legally binding. If WHO is used as a 
forum, another option is to take advantage of its 
constitutional power to adopt regulations under Article 21. 
Such regulations are opt-out instruments that come into 
force immediately for all Member States after their 
adoption by the World Health Assembly.36 Any legal 
mechanism at WHO should be paired with a sister 
agreement at the FAO and OIE to ensure compatibility 
across sectors.
An international agreement can also be negotiated by a 
subset of countries and then gradually adopted through 
incremental processes, such as the Anti-Personnel 
Mine Ban Convention and the Convention on Cluster 
Munitions. The advantage of starting with a small group 
of countries and then expanding is that the process can 
be swifter, more decisive, and of lower risk than if many 
countries are involved.36 Once a critical mass of countries 
has signed on, universal agreement can be sought as 
discussed previously.
An international legal mechanism can contain 
provisions for technical and fi nancial support for capacity 
building. One example is the Multilateral Fund for the 
Implementation of the Montreal Protocol, which assists 
LMICs to implement measures protecting the ozone 
layer.37 However, it would be diffi  cult for an international 
legal mechanism itself to mandate binding fi nancial 
obligations representing large innovation investments, 
as shown in debates surrounding the fi nancing of R&D 
for neglected diseases.38 Perhaps lessons can be learnt 
from international scientifi c collaborations such as the 
European Organization for Nuclear Research and the 
International Space Station.
Another possibility other than a legally binding 
instrument would be to create a UN agency, similar to 
UNAIDS, that is mandated with implementation of the 
coherent package. Led by high-level individuals, this 
agency could work through the political process and 
media to elucidate and persuade governments, health 
professionals, and the public, in a similar process to the 
Millennium Development Goals, but with a more formal 
organisational structure. This agency could work with 
partners such as GAVI Alliance and The Global Fund to 
Fight AIDS, Tuberculosis and Malaria to implement 
a plan of expanded appropriate access to eff ective 
antimicrobials and vaccines to reduce the need for 
such drugs.
Conclusion
Interdependent and interconnected problems need 
integrated solutions. Concurrent expansion of access 
and reduction of inappropriate use are necessary, and 
innovation rewards have to be delinked from unit-based 
sales revenues so that payments are not generally based 
on the number and price of drugs sold. Securing 
eff ective antimicrobials calls for systemic and inter-
dependent solutions.39,40
Global public goods, such as new antimicrobials, 
diagnostics, and treatment guidelines, should be 
secured through joint contributions and collaboration. 
Mobilisation of global solidarity will be necessary to 
secure resources and fi nancing for universal access and 
for national capacities for surveillance, responsible use, 
and infection control. Coordination of these functions 
will require not only leadership and political will, but 
also strong implementation and potentially enforcement 
mechanisms.41
Fortunately, securing eff ective antimicrobials has 
fi nally gained a place on the global agenda. Member 
States have endorsed WHO’s global action plan to 
combat antimicrobial resistance.42 The USA has 
launched a national strategy and an action plan to 
address antibiotic resistance, which awaits Congressional 
action.43 The Transatlantic Task Force on Antimicrobial 
Resistance between the USA and the European Union 
has put forward a series of recommendations for joint 
action.23 South Africa has agreed to an antimicrobial 
resistance national strategy framework.44 The UK has 
initiated an independent review on antimicrobial 
resistance, which stated that development of ten new 
highly eff ective drugs in the next decade would cost less 
than US$25 billion (or 0·03% of global gross domestic 
product [GDP]).45,46 A recent report to the Nordic Council 
of Ministers47 recommended a global investment of 
0·005% of annual global GDP over a 5-year period. 
There has also been a call for an intergovernmental 
antimicrobial panel, like the UN Intergovernmental 
Panel on Climate Change, which can synthesise and 
organise the available evidence to inform adoption and 
implementation of national policies.48 However, such a 
panel might be unnecessary, since a scientifi c consensus 
has already been reached regarding actions needed to 
secure eff ective antimicrobials.
Global actions need to integrate access to eff ective 
antimicrobials with infection prevention, responsible 
use of existing antimicrobials, surveillance, and 
innovation. These actions need to bridge the realms of 
public health, agriculture, animal husbandry, and trade. 
We have proposed a set of national and global 
recommendations (table 2) rooted in the analyses of 
this Lancet Series.1–4 Recommendations should be 
supported by strong implementation mechanisms that 
incorporate incentives for leaders to act on them, 
institutions that bring edicts into eff ect, and interests 
advocating their prioritisation.36,49 This implementation 
should lead to a new global institutional arrange-
ment, either an international legal mechanism or a 
UN agency.
Deadly bacterial pathogens are present in every country 
of the world, and new resistant pathogens are evolving 
every day. We need to secure and expand our arsenal of 
antimicrobials. Therefore, we urge world leaders to 
consider, commit to, and champion implementation of 
these recommendations.
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